After accumulating $86 billion in global sales, Amgen is still trying to keep Enbrel biosimilars off the market, Sandoz ...

US FDA approves Amgen’s Uplizna to treat IgG4-related disease: Thousand Oaks, California Saturday, April 5, 2025, 11:00 Hrs [IST] Amgen announced that the US Food and Drug Admin ...

The exemption may be short-lived if President Trump makes good on threats to use tariffs as leverage to bring drug production ...

Inebilizumab-cdon was previously approved by the FDA for neuromyelitis optica spectrum disorder (NMOSD) in adults who are ...

Advances Amgen’s Leadership in CD19 Directed, B-Cell Depletion Therapies for Serious Autoimmune Diseases Including NMOSD, IgG4-RD and gMG THOUSAND OAKS, CA, USA I April 3, 2025 I Amgen (NASDAQ:AMGN) ...

Amgen has announced that the Company has received approval from the U.S. Food and Drug Administration (FDA) for UPLIZNA as ...

Amgen (NASDAQ:AMGN) announced today that the U.S. Food and Drug Administration (FDA) has approved UPLIZNA as the first and onl ...

Inebilizumab-cdon (Uplizna; Amgen) was approved as the first and only treatment for immunoglobulin G4–related disease ...

Aldeyra Sets Sights on Dry Eye Disease with Reproxalap By April 2, the FDA will release its decision on Aldeyra Therapeutics’ RASP modulator reproxalap, which the Massachusetts biotech ... and ...

The case had been filed last year by Amgen after the state Prescription Drug Affordability Board determined that its big-selling medication called Enbrel is unaffordable and began a process to ...

In November 2023, Jack Ma posted an internal memo at Alibaba, urging the e-commerce giant he helped create to "correct its course." The message was as a rallying cry by one of China's most ...